Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Tidal Investments LLC

Tidal Investments LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.7% in the first quarter, Holdings Channel reports. The firm owned 40,890 shares of the biopharmaceutical company’s stock after selling 5,432 shares during the quarter. Tidal Investments LLC’s holdings in Gilead Sciences were worth $2,993,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Private Wealth Management Group LLC acquired a new position in Gilead Sciences in the fourth quarter worth about $29,000. Sachetta LLC acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $30,000. Palisade Asset Management LLC acquired a new position in Gilead Sciences in the first quarter valued at approximately $29,000. Rakuten Securities Inc. acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $33,000. Finally, Gladius Capital Management LP acquired a new position in Gilead Sciences in the fourth quarter valued at approximately $34,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 0.9 %

NASDAQ:GILD traded up $0.72 during trading hours on Thursday, hitting $76.78. 1,374,594 shares of the stock traded hands, compared to its average volume of 7,392,969. The firm has a 50 day moving average price of $68.37 and a 200 day moving average price of $70.90. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86. The firm has a market cap of $95.66 billion, a price-to-earnings ratio of 212.28, a PEG ratio of 3.43 and a beta of 0.18.

Analyst Ratings Changes

A number of equities analysts have commented on GILD shares. Royal Bank of Canada restated a “sector perform” rating and issued a $74.00 target price on shares of Gilead Sciences in a research note on Monday, July 1st. Raymond James raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price on the stock in a report on Monday, July 8th. Maxim Group dropped their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a report on Wednesday, April 24th. Finally, Oppenheimer reissued an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a report on Friday, April 19th. Twelve research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $81.81.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.